Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07554677

Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme – A Single-arm Study

Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme – A Single-arm Study — Recruiting • Non-phase study • Oncology • NCT07554677.

📅 04 Jun 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07554677
Sponsor
Queen's University, Belfast
Start
2026-06-10
ClinicaliQ Trial Snapshot
  • Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme – A Single-arm Study — Recruiting • Non-phase study • Oncology • NCT07554677.
  • What is being tested: A feasibility study evaluating a co-designed, pre-radiotherapy exercise programme consisting of 20-minute exercise sessions for patients with stage I-III non-small cell lung cancer undergoing radiotherapy treatment.
  • Patient eligibility overview: The trial includes adults with stage I-III non-small cell lung cancer who are scheduled to receive radiotherapy, with the programme designed to be delivered prior to commencing radiation treatment.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to understand the feasibility of a co-designed, pre-radiotherapy exercise programme for people with stage I-III non-small cell lung cancer. This involves people with lung cancer engaging in 20 minutes exercises sessions performed within the radiotherapy department and immediately before each treatment at a personalised intensity. The main questions it aims to answer are: To understand the acceptability of the exercise programme through monitoring recruitment rates, attendance of the exercise sessions, and adherence to prescribed exercise intensities. Adverse events will also be monitored to…

Eligibility Snapshot
  • : * Patients with clinically or histologically confirmed NSCLC stages 1-3. * Planned to receive treatment with curative intention radiation as primary treatment. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * At least 18 years of age. * Can understand and communicate in English. * Deemed safe to participate in moderate-intensity exercise and for ECG monitored maximal fitness test through the completion of a medical clearance form by their treating physician. * Able to provide written and informed consent.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
The Irish international rugby ‘trailblazer’ and her legacy of cancer awareness
Oncology · BBC Health · 30 Sep 2026
A prominent Irish rugby player's death from breast cancer highlights the importance of raising awareness about symptoms among younger women, even in…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
Free counselling for blood cancer patients
Oncology · BBC Health · 24 Sep 2026
Linc provides free counselling services accessible to blood cancer patients at all diagnostic stages and their families, addressing psychological support gaps in…
View brief →